GF-1004

About Genflow Biosciences

Genflow Biosciences is a pre-clinical, publicly traded biotech focused on the ambitious mission of developing gene therapies to slow or halt the aging process. Its core strategy centers on delivering a protective 'centenarian variant' of the SIRT6 gene via AAV vectors, with lead programs targeting Werner syndrome in humans and aging in dogs. The company has established key scientific and clinical partnerships and is led by a team with extensive experience in gene therapy and biotech entrepreneurship, positioning itself at the forefront of the emerging longevity therapeutics sector.

Therapeutic Areas